Dasatinib: a new step in molecular target therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The BCR-ABL fusion gene, resulting from the Philadelphia chromosome, drives chronic myeloid leukemia (CML) through unregulated tyrosine kinase activity.
• Imatinib is a tyrosine kinase inhibitor that improves CML outcomes, but resistance develops in a subset of patients.

Purpose of the Study:

• To evaluate dasatinib, a novel BCR-ABL inhibitor, as a treatment for CML, particularly in imatinib-resistant cases.
• To explore dasatinib's potential efficacy against other tyrosine kinase mutations, including KIT, and its application in solid tumors.

Main Methods:

• Clinical trials involving patients with CML treated with dasatinib.
• Preclinical studies assessing dasatinib's activity against imatinib-resistant mutations (e.g., KIT activation loop mutants) and in various human solid tumor cell lines.

Main Results:

• Dasatinib demonstrated high potency, approximately 300-fold greater than imatinib, and inhibited SRC family kinases.
• Preliminary clinical data indicate dasatinib is safe, well-tolerated, and induces objective responses in most patients with imatinib-resistant CML.
• Dasatinib effectively inhibits imatinib-resistant KIT mutants and induces apoptosis in relevant cell lines, showing preclinical activity in solid tumors.

Conclusions:

• Dasatinib is a promising therapeutic agent for CML, including imatinib-resistant forms, and warrants further investigation for durable response.
• Dasatinib's activity against KIT mutations and solid tumor cell lines suggests potential applications beyond CML treatment.